FHTX

Foghorn is a clinical-stage precision-oncology company with zero product revenue and, by its own MD&A, 'more than seven programs with one clinical-stage drug candidate currently in Phase 1 development' (FHD-909, a SMARCA2 inhibitor now run 50/50 with Lilly). Every dollar of the reported $30.9M FY2025 'revenue' is collaboration revenue tied to the December 2021 Lilly deal and its $300M upfront — not commercial sales — so the headline P/S of 10.1x is economically meaningless. The company remains deeply loss-making: FY2025 net income of -$74.3M, operating income of -$86.4M, and an operating margin of -279.5%. Losses have narrowed each year (from -$109M in FY2022 to -$74.3M) but the business consumes cash, not generates it.

The balance sheet is the disqualifier. Stockholders' equity is -$109M and liabilities/equity is -2.83x, with an accumulated deficit of -$632M. Most striking, cash and equivalents are just $80.9M against FY2025 operating cash burn of -$86.1M — roughly one year of runway at the current pace. The MD&A confirms the funding treadmill: a May 2024 underwriting agreement with Jefferies, TD and Evercore, and shares outstanding already up 5.6% YoY. A capital raise is not a question of if but when, and at a $311M market cap and $5.30 share price, dilution would be heavy.